Log in

Applied Therapeutics Stock Forecast, Price & News

+0.41 (+1.71 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $24.36
50-Day Range
MA: $25.43
52-Week Range
Now: $24.36
Volume242,403 shs
Average Volume227,315 shs
Market Capitalization$546.52 million
P/E RatioN/A
Dividend YieldN/A
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:APLT



Sales & Book Value

Annual SalesN/A



Market Cap$546.52 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
+0.41 (+1.71 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APLT News and Ratings via Email

Sign-up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions

How has Applied Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, APLT shares have decreased by 17.7% and is now trading at $24.36.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Applied Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Applied Therapeutics

When is Applied Therapeutics' next earnings date?

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Applied Therapeutics

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics (NASDAQ:APLT) issued its earnings results on Tuesday, August, 11th. The company reported ($1.27) EPS for the quarter, missing the Zacks' consensus estimate of ($0.69) by $0.58.
View Applied Therapeutics' earnings history

What price target have analysts set for APLT?

6 brokers have issued 1-year price targets for Applied Therapeutics' stock. Their forecasts range from $43.00 to $65.00. On average, they anticipate Applied Therapeutics' share price to reach $55.20 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price.
View analysts' price targets for Applied Therapeutics

Are investors shorting Applied Therapeutics?

Applied Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,610,000 shares, an increase of 32.0% from the July 15th total of 1,220,000 shares. Based on an average trading volume of 243,700 shares, the days-to-cover ratio is presently 6.6 days. Approximately 12.6% of the company's stock are sold short.
View Applied Therapeutics' Short Interest

Who are some of Applied Therapeutics' key competitors?

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include NVIDIA (NVDA), Verizon Communications (VZ), Walt Disney (DIS), Pfizer (PFE), AT&T (T), Advanced Micro Devices (AMD), Broadcom (AVGO), Alteryx (AYX), Boeing (BA) and Enbridge (ENB).

Who are Applied Therapeutics' key executives?

Applied Therapeutics' management team includes the following people:
  • Dr. Shoshana Shendelman Ph.D., Chairman, Founder, Pres, CEO & Sec. (Age 40)
  • Dr. Mark Joseph Vignola, Chief Financial Officer (Age 42)
  • Dr. Riccardo Perfetti, Chief Medical Officer (Age 59)

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Who are Applied Therapeutics' major shareholders?

Applied Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (8.72%), Orbimed Advisors LLC (5.43%), Driehaus Capital Management LLC (3.41%), Vanguard Group Inc. (2.78%), Emerald Advisers LLC (1.81%) and Emerald Mutual Fund Advisers Trust (1.60%). Company insiders that own Applied Therapeutics stock include Joel S Marcus, Leslie D Funtleyder, Real Estate Equitie Alexandria, Shoshana Shendelman and Stacy J Kanter.
View institutional ownership trends for Applied Therapeutics

Which major investors are selling Applied Therapeutics stock?

APLT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., and Orbimed Advisors LLC. Company insiders that have sold Applied Therapeutics company stock in the last year include Joel S Marcus, Leslie D Funtleyder, and Shoshana Shendelman.
View insider buying and selling activity for Applied Therapeutics

Which major investors are buying Applied Therapeutics stock?

APLT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Bamco Inc. NY, Driehaus Capital Management LLC, Kore Private Wealth LLC, Emerald Advisers LLC, Candriam Luxembourg S.C.A., UBS Group AG, and Vanguard Group Inc.. Company insiders that have bought Applied Therapeutics stock in the last two years include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman, and Stacy J Kanter.
View insider buying and selling activity for Applied Therapeutics

How do I buy shares of Applied Therapeutics?

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $24.36.

How big of a company is Applied Therapeutics?

Applied Therapeutics has a market capitalization of $546.52 million. Applied Therapeutics employs 4 workers across the globe.

What is Applied Therapeutics' official website?

The official website for Applied Therapeutics is www.appliedtherapeutics.com.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.